Reduction in atherosclerotic events: A retrospective study in an outpatient cardiology practice

Archives of Medical Science

Volumn 8, Issue 1, 2012, Pages 57-62

  Mercando, Anthony D ^a   Lai, Hoang M ^b   Aronow, Wilbert S ^b   Kalen, Phoenix ^b   Desai, Harit V ^b   Gandhi, Kaushang ^b   Sharma, Mala ^b   Amin, Harshad ^b   Lai, Trung M ^b  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Atherosclerosis; Cardiovascular drugs; Cerebrovascular events; Myocardial infarction

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILE ACID SEQUESTRANT; CALCIUM CHANNEL BLOCKING AGENT; CILOSTAZOL; CLOPIDOGREL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EZETIMIBE; FIBRIC ACID DERIVATIVE; FISH OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; NICOTINIC ACID; NITRATE; SITAGLIPTIN; SULFONYLUREA; TICLOPIDINE; WARFARIN;

ADULT; AGED; ARTICLE; CEREBROVASCULAR DISEASE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OUTPATIENT; RETROSPECTIVE STUDY; RISK REDUCTION;

EID: 84858125795     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2012.27282     Document Type: Article

References (23)

1. Centers for Disease Control and Prevention, http://www.cdc.gov/nchs/ fastats/deaths.htm. Accessed November 30, 2010.
2. Lai HM, Aronow WS, Rachdev A, et al. Incidence of mortality in 1,040 patients with coronary heart disease or hypertensive heart disease with normal and abnormal left ventricular ejection fraction and with normal and abnormal QRS duration. Arch Med Sci 2008; 4: 140-2.
3. Ramdeen N, Aronow WS, Chugh S, Asija A. Patients undergoing coronary angiography because of chest pain with hepatitis C virus have a higher prevalence of obstructive coronary artery disease than a control group. Arch Med Sci 2008; 4: 452-4.
4. Kannam H, Aronow WS, Chilappa K, et al. Association of the QRS duration on the resting electrocardiogram with the severity of coronary artery disease in 2,196 patients undergoing coronary angiography for suspected coronary artery disease. Arch Med Sci 2009; 5: 163-5.
5. 2 determined by intravascular ultrasound in patients with coronary artery calcium scores of 0-100, 100-200, 200-300, 300-400, and >400 determined by cardiac computer tomography. Arch Med Sci 2009; 5: 172-4.
6. Lleva P, Aronow WS, Amin H, et al. Prevalence of electrocardiographic abnormalities in patients with ischemic stroke, intracerebral hemorrhage, and suba - rachnoid hemorrhage. Arch Med Sci 2008; 4: 259-62.
7. Ravipati G, Aronow WS, Kumbar S, et al. Patients with diabetes mellitus with ischemic stroke have a higher hemoglobin A1c level and a higher serum low-density lipoprotein cholesterol level than diabetics without ischemic stroke. Arch Med Sci 2009; 5: 391-3.
8. Amin H, Aronow WS, Lleva P, et al. Prevalence of transthoracic echocardiographic abnormalities in patients with ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage. Arch Med Sci 2010; 6: 40-2.
9. Giaginis C, Klonaris C, Katsargyris A, et al. Correlation of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and retinoid X receptor-alpha (RXR-alpha) expression with clinical risk factors in patients with advanced carotid atherosclerosis. Med Sci Monit 2011; 17: CR381-91.
10. Hu P, Hu B, Wang J, et al. Modulation of vitamin D signaling is a potential therapeutic target to lower cardiovascular risk in chronic kidney disease. Med Sci Monit 2011; 17: HY14-20.
11. Wozniak G, Toska A, Saridi M, Mouzas O. Seotonin reuptake inhibitor antidepressants (SSRIs) against atherosclerosis. Med Sci Monit 2011; 17: RA205-14.
12. Setorki M, Asgary S, Eidi A, Haeri Rohani A. Effects of acute verjuice consumption with a high-cholesterol diet on some biochemical risk factors of atherosclerosis in rabbits. Med Sci Monit 2010; 16: BR124-30.
13. Cannon CP, Braunwald E, McCabe CH, et al.; Pravastatin or Atorvastatin Evaluation and Infection Therapy- Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-504.
14. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
15. Shepherd J, Blauw GJ, Murphy MB, et al. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623-30. (Pubitemid 35379733)
16. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53.
17. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8.
18. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058-68.
19. Beta-Blocker Heart Attack Study Group. The beta-blocker heart attack trial. JAMA 1981; 246: 2073-4.
20. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339: 489-97. (Pubitemid 28384881)
21. Bielecka-Dabrowa A, Aronow WS, Rysz J, Banach M. Current place of beta-blockers in the treatment of hypertension. Curr Vasc Pharmacol 2010; 8: 733-41.
22. Baigent C, Blackwell L, Collins R, et al.; Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60.
23. US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 150: 396-404.